I-PLB1004, eyenziwe yiBeijing Avistone Biotechnology Co., Ltd., sisixhobo esikhuselekileyo, esikhetha kakhulu, nesisebenzayo sokuthintela ukukhula kwe-epidermal growth factor receptor (EGFR-TKI) esisetyenziswa ekunyangeni umhlaza wamaphaphu ongengoweeseli ezincinci (NSCLC).
Ngomhla we-9 ku-Epreli, ngo-2025, iZiko loVavanyo lweeMveliso zezoNyango leSizwe (i-CDE) libonise ukuba i-PLB1004 yeBeijing Avistone Biotechnology yayijoliswe ukuba ifakwe kunyango oluphambili lwezigulane ezinomhlaza wamaphaphu ongengowe-METastatic non-small cell lung cancer (NSCLC) ezazinotshintsho lwe-EGFR, zafumana ukwanda kunye/okanye ukubonakaliswa kakhulu emva kokungaphumeleli konyango lwe-EGFR-TKI.
Iziphumo zokuqala zeklinikhi ze-PLB1004 ezidityaniswe neVebreltinib kunyango lwezigulane zomhlaza wamaphaphu ezingezizo iiseli ezincinci ezine-EGFR mutations, i-MET amplification okanye i-MET overexpression emva kwe-EGFR-TKI zabhengezwa kwiNkomfa yeHlabathi yoMhlaza wamaphaphu ka-2024.
Izigulana ezingamashumi amane anesine zifumene iVebreltinib 100mg kunye nePLB1004 160mg (n=15), iVebreltinib 150mg kunye nePLB1004 160mg (n=13), iVebreltinib 200mg kunye nePLB1004 80mg (n=3), okanye iVebreltinib 150mg kunye nePLB1004 80mg (n=13) kwaye zafakwa kuhlalutyo lokhuseleko lulonke. Phakathi kwezigulana ezingama-44 ezivavanyiweyo, ama-36.4% ezigulana ayene-metastases yobuchopho kwaye ama-86.4% ezigulana zazifumene ngaphambili i-EGFR-TKI yesizukulwana sesithathu, ngokwahlukeneyo. Iimpendulo ezijolise kuzo zonke iinqanaba zedosi zeVebreltinib kunye nePLB1004 zivavanyiwe, kunye neempendulo ezingaphelelanga (ii-PR) ezibonwe kwizigulane ezivavanywayo ze-19/32 (59.4%). Phakathi kwezigulana ezine-metastases yobuchopho, i-ORR yayiyi-75.0% (9/12). I-ORR yayiyi-58.6% (17/29) kwizigulana ezafumana i-EGFR-TKI yesizukulwana sesithathu ngaphambili. Ezona TRAE zixhaphakileyo yayikukurhawuzelela kunye ne-paronychia. Akukho zigulana ziye zayeka unyango ngenxa yeTRAEs.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
Email：myimmnet@163.com
Ixesha lokuthumela: Epreli-10-2025